| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Journal of the American Society of Nephrology, Vol 2, 1053-1062, Copyright © 1991 by American Society of Nephrology
EDITORIALS |
SG Rostand, JD Brunzell, RO Cannon 3d and RG Victor
Cardiovascular diseases are a leading cause of death in end-stage renal disease (ESRD) largely as a result of the progressively increasing age of ESRD patients and the broad constellation of uremia-associated factors that can adversely affect cardiac function. Hypertension, one of the leading causes of renal failure, is a major culprit in this process, causing left ventricular hypertrophy, cardiac chamber dilation, increased left ventricular wall stress, redistribution of coronary blood flow, reduced coronary artery vasodilator reserve, ischemia, myocardial fibrosis, heart failure, and arrhythmias. In addition to impairing the coronary microcirculation, hypertension may contribute to the development of atherosclerotic coronary artery disease, particularly in the presence of the many lipid abnormalities observed in ESRD. These patients have reduced high-density lipoprotein cholesterol and increased plasma triglyceride concentrations, and there is a defect in cholesterol transport. Other abnormalities that may contribute to atherosclerotic coronary artery disease in ESRD are reduced high-density lipoprotein cholesterol synthesis and reduced activity of the reverse cholesterol pathway. Treatment with fibric acids, nicotinic acids, and lovastatin may be useful in lowering cholesterol and triglyceride concentrations in some of these patients. The incidence of coronary artery disease in ESRD populations is difficult to determine. About 25 to 30% of ESRD patients with angina have no evidence of significant coronary artery disease, and an undetermined number have silent coronary disease. The presence of resting electrocardiographic abnormalities caused by hypertension or conduction defects makes it difficult to accurately diagnosis coronary artery disease in ESRD populations by noninvasive methods, including exercise testing and thallium scintigraphy with or without the use of dipyridamole. Hypotension is a frequent complication of the dialytic process. Many factors have been implicated, including autonomic neuropathy. There is no consensus on the function of the efferent limb of the sympathetic nervous system. The afferent limb (arterial baroreflex function) is felt to be impaired. Further, there may be defects in the ability of the cardiovascular system to respond to sympathetic nerve activity. Most studies of autonomic function have used indirect measurements. Studies are underway that use techniques to assess sympathetic function directly. Such experiments with microneuropathy suggest greater skeletal sympathetic muscle discharge in uremic patients than in normal patients.
This article has been cited by other articles:
![]() |
T. Hayashi, Y. Obi, T. Kimura, K.-i. Iio, S. Sumitsuji, Y. Takeda, Y. Nagai, and E. Imai Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2936 - 2942. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Genovesi, O. Bracchi, P. Fabbrini, E. Luisetto, M. R. Vigano, D. Lucini, M. Malacarne, A. Stella, and M. Pagani Differences in heart rate variability during haemodialysis and haemofiltration Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2256 - 2262. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tatematsu, S. Wakino, T. Kanda, K. Homma, K. Yoshioka, K. Hasegawa, N. Sugano, M. Kimoto, T. Saruta, and K. Hayashi Role of Nitric Oxide-Producing and -Degrading Pathways in Coronary Endothelial Dysfunction in Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 741 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dikow, L. P. Kihm, M. Zeier, J. Kapitza, J. Tornig, K. Amann, C. Tiefenbacher, and E. Ritz Increased Infarct Size in Uremic Rats: Reduced Ischemia Tolerance? J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1530 - 1536. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Sadeghi, G. W. Stone, C. L. Grines, R. Mehran, S. R. Dixon, A. J. Lansky, M. Fahy, D. A. Cox, E. Garcia, J. E. Tcheng, et al. Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction Circulation, December 2, 2003; 108(22): 2769 - 2775. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Hocher, R. Ziebig, C. Altermann, R. Krause, G. Asmus, C.-M. Richter, T. Slowinski, P. Sinha, and H.-H. Neumayer Different Impact of Biomarkers as Mortality Predictors among Diabetic and Nondiabetic Patients Undergoing Hemodialysis J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2329 - 2337. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Leoncini, F. Viazzi, D. Parodi, S. Vettoretti, E. Ratto, M. Ravera, C. Tomolillo, M. Del Sette, G. P. Bezante, G. Deferrari, et al. Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension Hypertension, July 1, 2003; 42(1): 14 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hausberg, M. Kosch, P. Harmelink, M. Barenbrock, H. Hohage, K. Kisters, K. H. Dietl, and K. H. Rahn Sympathetic Nerve Activity in End-Stage Renal Disease Circulation, October 8, 2002; 106(15): 1974 - 1979. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Ruilope, D. J. van Veldhuisen, E. Ritz, and T. F. Luscher Renal function: the Cinderella of cardiovascular risk profile J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1782 - 1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. AMANN, G. MIL TENBERGER-MIL TENYI, A. SIMONOVICIENE, A. KOCH, S. ORTH, and E. RITZ Remodeling of Resistance Arteries in Renal Failure: Effect of Endothelin Receptor Blockade J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2040 - 2050. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. RUILOPE, A. SALVETTI, K. JAMERSON, L. HANSSON, I. WARNOLD, H. WEDEL, and A. ZANCHETTI Renal Function and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension Optimal Treatment (HOT) Study J. Am. Soc. Nephrol., February 1, 2001; 12(2): 218 - 225. [Abstract] [Full Text] |
||||
![]() |
K. Amann and E. Ritz Microvascular disease--the Cinderella of uraemic heart disease Nephrol. Dial. Transplant., October 1, 2000; 15(10): 1493 - 1503. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. KIMURA, F. GEJYO, S. SUZUKI, and R. MIYAZAKI The C677T Methylenetetrahydrofolate Reductase Gene Mutation in Hemodialysis Patients J. Am. Soc. Nephrol., May 1, 2000; 11(5): 885 - 893. [Abstract] [Full Text] |
||||
![]() |
L. Labrousse, C. de Vincentiis, F. Madonna, C. Deville, X. Roques, and E. Baudet Early and long term results of coronary artery bypass grafts in patients with dialysis dependant renal failure Eur. J. Cardiothorac. Surg., May 1, 1999; 15(5): 691 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Schmidt, S. Yokota, T. S. Tracy, M. I. Sorkin, and C. Baylis Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis Am J Physiol Renal Physiol, May 1, 1999; 276(5): F794 - F797. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. KIMURA, F. GEJYO, T. YAMAGUCHI, S. SUZUKI, T. IMURA, R. MIYAZAKI, and M. ARAKAWA A Cholesteryl Ester Transfer Protein Gene Mutation and Vascular Disease in Dialysis Patients J. Am. Soc. Nephrol., February 1, 1999; 10(2): 294 - 299. [Abstract] [Full Text] |
||||
![]() |
J. TÖRNIG, M.-L. GROSS, A. SIMONAVICIENE, G. MALL, E. RITZ, and K. AMANN Hypertrophy of Intramyocardial Arteriolar Smooth Muscle Cells in Experimental Renal Failure J. Am. Soc. Nephrol., January 1, 1999; 10(1): 77 - 83. [Abstract] [Full Text] |
||||
![]() |
J. Mattana, C. Effiong, R. Gooneratne, and P. C. Singhal Outcome of Stroke in Patients Undergoing Hemodialysis Arch Intern Med, March 9, 1998; 158(5): 537 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Robinson, A. Gupta, V. Dennis, K. Arheart, D. Chaudhary, R. Green, P. Vigo, E. L. Mayer, J. Selhub, M. Kutner, et al. Hyperhomocysteinemia Confers an Independent Increased Risk of Atherosclerosis in End-Stage Renal Disease and Is Closely Linked to Plasma Folate and Pyridoxine Concentrations Circulation, December 1, 1996; 94(11): 2743 - 2748. [Abstract] [Full Text] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673